Latest news with #Masimo
Forbes
6 days ago
- Business
- Forbes
Denon's Latest AH-C840NCW Wireless Earbuds Are Now Shipping
The new wireless earbuds announced by Denon last month are now shipping so I thought I would tell you a little more about these mid-priced earbuds that go up against Apple's AirPods. Since the announcement, Denon has been sold by its owner Masimo to Harman International, along with its stablemates Marantz and B&W. But it's business as usual at one of Japan's oldest and most venerable audio brands. The new Denon AH-C840NCW are true wireless earbuds with silicone ear tips and adaptive hybrid active noise cancellation for a more immersive listening experience. The noise cancelation is Hybrid ANC which automatically adjusts the level of noise cancellation using two microphones in each earpiece to monitor sound. The ANC also has a transparency mode that enables users to stay aware of ambient noise if needed. Adaptive hybrid ANC differs from regular Adaptive ANC. With normal Adaptive ANC, the amount of noise cancellation applied is purely based on surrounding sounds. Hybrid ANC combines both feedforward and feed-backward circuitry to capture and cancel noise across a wider range of frequencies. A full charge of the battery inside the storage case can provide up to 35 hours of playtime before a top-up is necessary. A full charge of the earbuds can yield up to 10 hours of listening time before they need to go back in the case. The earbuds also support wireless charging as well as the usual USB-C. That figure depends on volume levels, the audio codec being used and whether ANC is turned on. With ANC turned on, the earbuds deliver up to seven hours of listening time from a single charge, with up to 24 hours of listening on the go using the charging case. A five-minute burst charge can provide about an hour of listening time. These days, most people rely on their earbuds for making phone calls. It's important to have microphones that can pick up the user's voice. To handle this, Denon uses two mics and noise canceling to filter out some of the ambient sound that the mics would normally pick up. This can enhance call clarity in noisy spaces. Currently, Bluetooth technology is going through a transition with many manufacturers of earbuds and other devices moving to the new Bluetooth LE standard. Bluetooth LE Audio is a power-efficient version of Bluetooth that's designed for low-bandwidth, intermittent data transmission, making it suitable for battery-powered devices, wearables and smart home products. Bluetooth LE consumes less energy than Classic Bluetooth by quickly establishing and terminating connections as well as optimizing small data transfers. What's more, Bluetooth LE Audio supports high-quality, low-power audio streaming with audio codecs like LDAC and LC3. The AH-C840NCW earbuds also support Auracast. This is a new Bluetooth technology that can broadcast to multiple earbuds or speakers. For example, a sports bar might have a TV showing a football game but with the sound off. If the TV supports Auracast, anyone with a pair of Auracast-compatible earbuds or headphones can pick up the audio signal from the TV wirelessly and listen to the ball game commentary without disturbing anyone around them. It's a little like the inductive loops used for hearing aid wearers. As well as supporting Auracast, the Denon AH-C840NCW also have multipoint connectivity which means the earbuds can pair with two Bluetooth devices at once. One device could be a phone for business calls, while the other could be a tablet showing a movie or a digital audio player streaming Tidal. With multipoint, a user can switch seamlessly between two devices. For example, they might be watching a movie on their iPad when an important business call comes in on their smartphone. One press and the user can seamlessly switch to take the call, automatically pausing the movie until the call is ended. To get the most from these new earbuds, Denon has updated its smartphone app which offers customization of the AH-C840NCW. The Denon Headphones app lets the user adjust sound settings, touch controls, manage ANC levels and apply any future firmware updates for optimal performance. Finally, the earbuds support voice assistants like Siri or Google Assistant when connected to a compatible device. They include protection against sweat and water thanks to a waterproof rating of IPX4 which means they are resistant to sweat and water splashes, making them suitable for workouts and outdoor activities. The Denon AH-C840NCW true wireless earbuds are shipping now from Denon's website and through authorized retailers priced at $159 / £159 / €159.
Business Wire
7 days ago
- Health
- Business Wire
Masimo to Present in the Jefferies Global Healthcare Conference
IRVINE, Calif.--(BUSINESS WIRE)-- Masimo A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio. Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET ® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies. 1 Masimo SET ® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates, 2 improve CCHD screening in newborns, 3 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs. 4-7 Masimo SET ® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world, 8 and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2024 Newsweek World's Best Hospitals listing. 9 In 2005, Masimo introduced rainbow ® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb ®), oxygen content (SpOC™), carboxyhemoglobin (SpCO ®), methemoglobin (SpMet ®), Pleth Variability Index (PVi ®), RPVi™ (rainbow ® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root ® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine ® Brain Function Monitoring, O3 ® Regional Oximetry, and ISA™ Capnography with NomoLine ® sampling lines. Masimo's family of continuous and spot-check monitoring Pulse CO-Oximeters ® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7 ®, Radius PPG ®, and Radius VSM™, portable devices like Rad-67 ®, fingertip pulse oximeters like MightySat ® Rx, and devices available for use both in the hospital and at home, such as Rad-97 ® and the Masimo W1 ® Medical Watch. Masimo hospital and home automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris ® Gateway, iSirona™, Patient SafetyNet, Replica ®, Halo ION ®, UniView ®, UniView :60™, and Masimo SafetyNet ®. Its growing portfolio of health and wellness solutions includes Radius T° ® and Masimo W1 Sport. Additional information about Masimo and its products may be found at Published clinical studies on Masimo products can be found at RPVi has not received FDA 510(k) clearance and is not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium. References Published clinical studies on pulse oximetry and the benefits of Masimo SET ® can be found on our website. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO 2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338. Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287. Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012. McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302. McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. Estimate: Masimo data on file. Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI and ORI are trademarks or registered trademarks of Masimo Corporation
Yahoo
20-05-2025
- Business
- Yahoo
MASI Q1 Earnings Call: Revenue Tops Expectations, Focus Shifts to Healthcare Core Amid Tariff Headwinds
Medical tech company Masimo (NASDAQ:MASI) reported Q1 CY2025 results topping the market's revenue expectations , with sales up 9.5% year on year to $372 million. The company expects the full year's revenue to be around $1.52 billion, close to analysts' estimates. Its non-GAAP profit of $1.36 per share was 12.6% above analysts' consensus estimates. Is now the time to buy MASI? Find out in our full research report (it's free). Revenue: $372 million vs analyst estimates of $367.9 million (9.5% year-on-year growth, 1.1% beat) Adjusted EPS: $1.36 vs analyst estimates of $1.21 (12.6% beat) Adjusted EBITDA: $123.8 million vs analyst estimates of $108.5 million (33.3% margin, 14.1% beat) Management lowered its full-year Adjusted EPS guidance to $4.98 at the midpoint, a 5.2% decrease Operating Margin: 21%, up from 15.6% in the same quarter last year Free Cash Flow Margin: 7.7%, down from 11.1% in the same quarter last year Constant Currency Revenue rose 10.5% year on year (-12.5% in the same quarter last year) Market Capitalization: $8.44 billion Masimo's first quarter results were driven by double-digit growth in core healthcare sales, margin expansion, and operational efficiencies. CEO Katie Szyman attributed performance to strong demand for patient monitoring products, a successful large contract renewal, and improved cost controls. She also cited early progress in her commercial strategy and highlighted the company's commitment to innovation as foundational for future growth. Looking ahead, management's guidance reflects the impact of new tariffs and continued investments in commercial and R&D initiatives. CFO Micah Young described the tariff environment as fluid, noting that mitigation plans are in progress but difficult to quantify for the full year. The company's outlook is further shaped by the sale of its consumer audio business, with proceeds expected to support share repurchases. Szyman acknowledged ongoing uncertainty from tariffs and emphasized Masimo's focus on operational execution and margin discipline. Masimo's management identified several drivers behind Q1 performance and upcoming changes to its business focus. The sale of the consumer audio division and a renewed emphasis on healthcare technology are central to its evolving strategy. Divestiture of Sound United: Masimo entered an agreement to sell its consumer audio business, Sound United, allowing the company to concentrate resources on its healthcare segment. Management stated that the sale will help sharpen the company's focus on patient monitoring and hospital solutions. Operational margin gains: Operating margin improvement was attributed to last year's cost optimization measures and a shift towards higher-value healthcare products. CFO Micah Young noted that these actions resulted in a 750 basis point annual increase. Sales force restructuring: CEO Katie Szyman outlined a transition from product-based to regionally-focused sales teams. This shift is intended to leverage the full product portfolio and increase market penetration for advanced monitoring categories such as capnography and hemodynamics. Product innovation pipeline: Szyman highlighted next-generation patient monitors with AI-based algorithms as a key area of investment. These upcoming launches aim to expand Masimo's presence in acute and post-acute care settings. Tariff mitigation planning: Management discussed detailed scenario planning to address new U.S. and China tariffs. Young explained that supply chain adjustments and sourcing changes are under evaluation, with mitigation steps expected to be phased in as regulatory clarity improves. Masimo's forward-looking performance will depend on its ability to offset tariff pressures, execute its healthcare strategy, and maintain commercial momentum while investing in innovation. Tariff cost management: Management is actively scenario-planning to mitigate the impact of recently imposed tariffs, including supply chain shifts and potential pricing adjustments, with the goal of reducing margin pressure through 2025. Healthcare business refocus: The sale of the consumer audio division will free up resources to accelerate investments in patient monitoring technologies, AI-driven products, and sales force expansion—all positioned as growth catalysts for the core business. Operational investments and risks: Increased spending on commercial excellence and R&D, coupled with macroeconomic uncertainties such as labor costs and regulatory shifts, may create short-term margin volatility even as management expects long-term leverage. Frederick Wise (Stifel): Asked about the revenue and margin impact of a large contract and how underlying growth trends will normalize next quarter. Management explained the timing effect and stated that underlying demand remains strong, with seasonality expected to drive Q2 results. Vik Chopra (Wells Fargo): Queried whether tariffs will affect long-term margin goals and sought clarification on use of proceeds from the Sound United sale. CFO Micah Young confirmed ongoing margin expansion is expected and that share repurchases are prioritized over debt repayment. Jason Bednar (Piper Sandler): Requested insight into OEM partner signals on hospital spending and the rationale for confidence in guidance despite a recent cybersecurity incident. Management cited recurring revenue strength and robust protocols for addressing the incident. Mike Matson (Needham): Probed the strategy for hemodynamic monitoring and whether share repurchases will take precedence over debt repayment. CEO Szyman described the plan to integrate hemodynamics into next-gen monitors and focus on mid-to-low acuity hospital segments. Matt Taylor (Jefferies): Sought details on the margin expansion potential and the cadence of tariff impacts throughout the year. Management highlighted ongoing investments and explained that tariff effects will be weighted toward the fourth quarter. In the coming quarters, the StockStory team will monitor (1) the progress of Masimo's sales force restructuring and its effect on new product adoption, (2) execution of supply chain and sourcing adjustments in response to tariffs, and (3) the pace and success of innovation in AI-based patient monitoring. Updates on the Sound United sale closing and deployment of proceeds will also be key markers for fundamental performance. Masimo currently trades at a forward P/E ratio of 28.7×. Should you load up, cash out, or stay put? Find out in our free research report. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Los Angeles Times
12-05-2025
- Business
- Los Angeles Times
Samsung's Harman to Acquire Masimo's Sound United Consumer Audio Business for $350 Million
Irvine-based Masimo Corp. agreed to sell its Sound United consumer audio business to HARMAN International Industries Inc., a subsidiary of Samsung Electronics Co., for $350 million. The deal is expected to close by the end of 2025. 'Finding the right home for this business has been a stated priority of the new board from day one, and this transaction represents an important milestone as we continue to position the company to achieve our goals of accelerating revenue growth while delivering disciplined margins. Masimo has tremendous opportunities ahead, and we are confident we have the right healthcare-focused strategy, experienced leadership team and culture of innovation in place to build on our significant positive momentum,' said Quentin Koffey, vice chairman of Masimo's board of directors, in a statement. Sullivan & Cromwell served as legal adviser to Masimo. Information for this article was sourced from Harman.
Yahoo
09-05-2025
- Business
- Yahoo
Do You Believe in the Growth Potential of Masimo Corporation (MASI)?
Baron Funds, an investment management company, released its 'Baron Health Care Fund' first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.54% (Institutional Shares) in the quarter compared to a 3.87% gain for the Russell 3000 Health Care Index (benchmark) and a 4.72% decline for the Russell 3000 Index (the Index). The fund trailed the benchmark due to stock selection and, to a lesser extent, active sub-industry weights. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Masimo Corporation (NASDAQ:MASI). Incorporated in 1989, Masimo Corporation (NASDAQ:MASI) is a medical technology company that provides various patient monitoring technologies, automation, and connectivity solutions. The one-month return of Masimo Corporation (NASDAQ:MASI) was -0.21%, and its shares gained 26.13% of their value over the last 52 weeks. On May 8, 2025, Masimo Corporation (NASDAQ:MASI) stock closed at $153.58 per share with a market capitalization of $8.327 billion. Baron Health Care Fund stated the following regarding Masimo Corporation (NASDAQ:MASI) in its Q1 2025 investor letter: "We initiated a position in Masimo Corporation (NASDAQ:MASI), a medical device company that manufactures and sells a variety of non-invasive patient monitoring technologies. Masimo is the market leader in pulse oximetry, which measures oxygen saturation of arterial blood. The company's differentiated pulse oximetry technology overcomes the limitations of conventional pulse oximetry by maintaining accuracy in the presence of motion and low perfusion. Masimo SET is the primary pulse oximetry technology used in the top 10 U.S. hospitals. The company has significant intellectual property protection around its technology as well as multi-year customer contracts, creating barriers to entry. The business benefits from a highly recurring revenue model driven by disposable sensors. A team of doctors and nurses in the operating room, utilizing a variety of Masimo's medical technology. Masimo Corporation (NASDAQ:MASI) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 35 hedge fund portfolios held Masimo Corporation (NASDAQ:MASI) at the end of the fourth quarter which was 30 in the previous quarter. Masimo Corporation's (NASDAQ:MASI) first quarter revenue grew 10% to $372 million. While we acknowledge the potential of Masimo Corporation (NASDAQ:MASI) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
